Iptacopan cleared Germany's AMNOG via an orphan-drug shortcut; crovalimab, without that status, must win the same substantial-benefit finding directly.

Iptacopan's German launch cleared both AMNOG hurdles at once, and by different routes. As an orphan-designated therapy, its additional benefit counted as established through EMA approval alone under SGB V paragraph 35a, so IQWiG never had to build a head-to-head dossier against anti-C5 therapy. The G-BA then went further on 19 December 2024, finding a substantial additional benefit specifically on quality of life, real leverage GKV-Spitzenverband can use in price negotiations. Crovalimab has no such shortcut: its dossier, submitted 12 September 2024, sits under active IQWiG assessment on the standard comparator track, meaning it must win its own substantial-benefit finding against whatever comparator G-BA designates, likely iptacopan itself.

That sets the readiness bar for any PNH entrant without orphan standing. Confirm orphan designation status early, since it changes the entire AMNOG pathway. Build the clinical evidence package against the comparator G-BA is likely to choose, iptacopan itself, not just eculizumab or ravulizumab. And engage Germany's concentrated referral network well before the AMNOG clock starts: the German PNH Register at Ulm's Institute for Clinical Transfusion Medicine and Immunogenetics, and the West German Cancer Center at Essen, since both feed the International PNH Registry data a benefit dossier will need to cite.

Without orphan status, the AMNOG fight against iptacopan starts from scratch.

Five questions this report answers:

Q1 - What clinical or regulatory standing does a new PNH entrant need for Germany's orphan AMNOG shortcut?

Q2 - What comparator and benefit threshold will G-BA apply now that iptacopan set a substantial-benefit precedent?

Q3 - Which German institutions and registries must a pre-launch PNH team engage, and on what timeline?

Q4 - What primary sources does AXLRx use to verify G-BA and IQWiG findings for this brief?

Q5 - What does a new PNH entrant need ready to succeed in Germany's AMNOG process after iptacopan?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #Germany #AMNOG #LaunchReadiness #RareDisease

Live report page:  https://axlrx.ai/pnh/germany/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/